Keywords: Biosimilars, Sandoz, Novartis, Filgrastim, Pegfilgrastim, Amgen, Zarzio

Sandoz initiates two more Phase III biosimilar trials

Article | 20 January 2012

Print This

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), says that it has initiated two milestone Phase III ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in